QCG
BNR

Quadrant Capital Group’s Burning Rock Biotech BNR Stock Holding History

Quadrant Capital Group’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed – – 2517
2021
Q3 		$0 Sell
2
-2
-50% -$445 ﹤0.01% 2506
2021
Q2 		$1K Buy
+4
New +$1.18K ﹤0.01% 2224

Other funds holding BNR

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Quadrant Capital Group's BNR Position: Q4 2021 in Review

Quadrant Capital Group sold out of Burning Rock Biotech (BNR) in Q4 2021, closing a stake of 2 shares.

Quadrant Capital Group first reported a position in BNR in Q2 2021 and held it in 2 quarters. The position peaked at $1K in Q2 2021. 62 funds tracked by Wall St. Rank hold BNR as of Q4 2021.

  • Quadrant Capital Group reported no remaining Burning Rock Biotech position as of Q4 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 2 Burning Rock Biotech shares in Q4 2021.
  • Quadrant Capital Group first reported a position in Burning Rock Biotech in Q2 2021 and held it in 2 quarters.
  • Quadrant Capital Group's Burning Rock Biotech position peaked at $1K in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q4 2021.

Based on Quadrant Capital Group's 13F filing for Q4 2021, filed 1 Feb 2022.